What is Resistomap?
Resistomap operates within the critical medtech sector, providing an advanced platform for monitoring antibiotic resistance. This capability is vital in addressing the growing global health challenge posed by antimicrobial resistance (AMR). By offering precise and timely data, Resistomap empowers healthcare providers and researchers to make informed decisions, thereby contributing to more effective treatment strategies and public health outcomes. The company's focus on this specialized area positions it as a key player in the fight against a pervasive and escalating threat.
How much funding has Resistomap raised?
Resistomap has raised a total of $2.2M across 1 funding round:
Angel/Seed
$2.2M
Angel/Seed (2023): $2.2M with participation from Business Finland, Gaingels, and Ananda Ventures
Key Investors in Resistomap
Business Finland
Business Finland is a Finnish public organization that provides innovation funding and internationalization services, supporting Finnish companies in their growth and global expansion.
Gaingels
Gaingels is a leading investment syndicate focused on supporting the LGBTQ community and allies in venture capital, investing in companies with inclusive teams and diverse leadership across various sectors.
Ananda Ventures
Ananda Impact Ventures partners with founders to invest in innovative technologies that address critical challenges in areas such as decarbonization, healthcare, and environmental sustainability, aiming to create a sustainable future.
What's next for Resistomap?
The recent major strategic investment signals a significant milestone for Resistomap, likely enabling the company to accelerate its product development, expand its market reach, and further enhance its monitoring capabilities. This infusion of capital, part of a larger enterprise-level funding effort, suggests strong investor confidence in Resistomap's technology and its potential to address a critical global health issue. Future endeavors may include scaling operations, forging new partnerships, and advancing research to combat antibiotic resistance more effectively.
See full Resistomap company page
